These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10494757)

  • 1. High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria.
    Ariëns RA; Moia M; Rivolta E; Ponticelli C; Mannucci PM
    Thromb Haemost; 1999 Sep; 82(3):1020-3. PubMed ID: 10494757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.
    Ariëns RA; Alberio G; Moia M; Mannucci PM
    Thromb Haemost; 1999 Feb; 81(2):203-7. PubMed ID: 10063992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
    Lizakowski S; Zdrojewski Z; Jagodzinski P; Rutkowski B
    Scand J Urol Nephrol; 2007; 41(3):237-42. PubMed ID: 17469034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
    Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood viscosity and haemostasis in the nephrotic syndrome.
    McGinley E; Lowe GD; Boulton-Jones M; Forbes CD; Prentice CR
    Thromb Haemost; 1983 Jun; 49(3):155-7. PubMed ID: 6410531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
    Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of the protein C-protein S system in glomerulopathies and nephrotic syndrome].
    Rostoker G; Gouault-Heilmann M; Levent M; Lang P; Robeva R; Lagrue G
    Nouv Rev Fr Hematol (1978); 1986; 28(6):359-63. PubMed ID: 2951650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease.
    Eling M; Stephens AC; Oragui EE; Rivers RP; Levin M
    Thromb Haemost; 2001 Feb; 85(2):240-4. PubMed ID: 11246540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased tissue factor pathway inhibitor (TFPI) and coagulation in patients with insulin-dependent diabetes mellitus.
    Leurs PB; van Oerle R; Wolffenbuttel BH; Hamulyak K
    Thromb Haemost; 1997 Mar; 77(3):472-6. PubMed ID: 9065996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
    Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R
    Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein C and protein S in pediatric nephrotic patients.
    Yermiahu T; Shalev H; Landau D; Dvilansky A
    Sangre (Barc); 1996 Apr; 41(2):155-7. PubMed ID: 9045358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
    Alban S; Gastpar R
    Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
    Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
    J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and urinary heparin cofactor II levels in patients with nephrotic syndrome.
    Grau E; Oliver A; Félez J; Barceló P; Fernandez C; Ballarin JA; Fontcuberta J; Rutllant ML
    Thromb Haemost; 1988 Oct; 60(2):137-40. PubMed ID: 3217913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High plasma levels of protein C activity and antigen in the nephrotic syndrome.
    Mannucci PM; Valsecchi C; Bottasso B; D'Angelo A; Casati S; Ponticelli C
    Thromb Haemost; 1986 Feb; 55(1):31-3. PubMed ID: 3754658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state.
    Dahm A; Rosendaal FR; Andersen TO; Sandset PM
    Br J Haematol; 2006 Feb; 132(3):333-8. PubMed ID: 16409298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers.
    Morange PE; Renucci JF; Charles MA; Aillaud MF; Giraud F; Grimaux M; Juhan-Vague I
    Thromb Haemost; 2001 Jun; 85(6):999-1003. PubMed ID: 11434709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between adiponectin levels and degree of proteinuria in patients with nephrotic and non-nephrotic proteinuria.
    Oguz Y; Yilmaz MI; Acikel C; Eyileten T; Caglar K; Oktenli C; Yenicesu M; Vural A
    Ren Fail; 2009; 31(1):29-35. PubMed ID: 19142807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in circadian variations of tissue factor pathway inhibitor type 1 between able-bodied and spinal cord injured.
    Dahm AE; Iversen PO; Hjeltnes N; Sandset PM
    Thromb Res; 2006; 118(2):281-7. PubMed ID: 16139333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormalities of homocysteine and B vitamins in the nephrotic syndrome.
    Podda GM; Lussana F; Moroni G; Faioni EM; Lombardi R; Fontana G; Ponticelli C; Maioli C; Cattaneo M
    Thromb Res; 2007; 120(5):647-52. PubMed ID: 17276499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.